Data from the phase 3 SENTRY trial showed that adding selinexor (Xpovio) to ruxolitinib (Jakafi) significantly improved spleen responses in patients with JAK inhibitor-naive myelofibrosis. The study met one of its two co-primary endpoints, with 49.8% of patients receiving the combination achieving at least a 35% reduction in spleen volume at week 24, compared with […]
Researchers at The University of Texas MD Anderson Cancer Center have created the first comprehensive spatial atlas of tertiary lymphoid structures (TLSs), specialized immune-cell hubs found within tumors. Led by Linghua Wang, the team used AI and spatial omics technologies to analyze 340 tumor samples from 12 cancer types. The study found that a TLS’s
AI-Driven TLS Spatial Atlas Improves Cancer Prognosis and Immunotherapy Prediction Read More »
A new study has clarified the role of NOTCH1 in head and neck squamous cell carcinoma (HNSCC), showing that it functions as a tumor suppressor rather than an oncogene. Researchers found that activating NOTCH1 signaling in both mutated and wild-type cancer cells reduced tumor growth, lowered cancer stem cell activity, and triggered changes linked to
The European Union has approved a subcutaneous version of Sarclisa (isatuximab) delivered through the CirCLIQ on-body injector, making it the first cancer therapy approved for wearable injector administration. The approval covers all of the drug’s existing EU indications for multiple myeloma, including newly diagnosed and relapsed or refractory disease. The decision was based on results
EU Approves First Wearable Cancer Drug Injector for Multiple Myeloma Patients Read More »
Early results from an ongoing phase 1/2 clinical trial show promising activity for vopimetostat, an oral PRMT5 inhibitor, when combined with RAS-targeted therapies in patients with advanced, previously treated pancreatic cancer that has an MTAP deletion. The strongest results were seen with vopimetostat plus daraxonrasib in patients with RAS-mutant pancreatic cancer. Among 12 evaluable patients,
The phase 3 RECITE trial evaluated romiplostim (Nplate) versus placebo for chemotherapy-induced thrombocytopenia (CIT) in patients with gastrointestinal cancers receiving oxaliplatin-based chemotherapy. CIT often forces chemotherapy delays or dose reductions, potentially compromising treatment effectiveness. Romiplostim significantly improved treatment continuity. Eighty-four percent of patients receiving romiplostim required no CIT-related chemotherapy dose modifications during cycles 2 and
Long-term results from the phase 3 NCT01812902 tria suggest that extended pelvic lymph node dissection (ePLND) during radical prostatectomy may provide a significant survival benefit for patients with high-grade prostate cancer. The study enrolled 300 men with intermediate- or high-risk prostate cancer and followed them for a median of nearly 11 years. While extended lymph node
A large real-world analysis suggests that zanubrutinib (Brukinsa) may provide better outcomes than acalabrutinib (Calquence) and ibrutinib (Imbruvica) when used as first-line treatment for older patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Researchers analyzed Medicare data from 10,523 patients aged 65 years and older who began treatment between January 2020 and
Real-World Study Finds Zanubrutinib Improves Survival in Older Patients With CLL and SLL Read More »
Results from the phase 3 RINGSIDE trial showed that varegacestat (AL102) significantly improved outcomes for patients with progressing desmoid tumors. The findings have supported a New Drug Application submitted to the FDA in April 2026. The global study enrolled 156 adults with desmoid tumors that had progressed within the previous year and randomly assigned them
Phase 3 Trial Shows Varegacestat Significantly Improves Outcomes in Desmoid Tumors Read More »
The U.S. FDA has approved FoundationOne CDx, a tissue-based companion diagnostic test, to identify patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative advanced or metastatic breast cancer who may benefit from treatment with inavolisib (Itovebi) combined with palbociclib (Ibrance) and fulvestrant (Faslodex). The approval provides an important alternative to the previously authorized blood-based FoundationOne Liquid CDx, helping
FDA Approves New Test to Expand Access to Targeted Breast Cancer Therapy Read More »